The development of a dedicated leadership team was identified as a pivotal priority in the Cancer Center strategic planning process to ensure consultative, transparent and effective decision-making. This was accomplished in the last project period through a combination of new appointments, creation of new leadership positions in the Cancer Center and reconfiguration of existing roles for optimal impact on the cancer research agenda. As part of this reorganization. Dr. Rauscher was appointed as a the sole Deputy Director of the Cancer Center with a codified succession plan should the need arise to replace the current Director, and a second Deputy Director position that was previously filled by Dr. Herlyn was eliminated. Since the introduction of these changes, the senior leadership team has worked well together, guiding an extensive and transparent consultative process that involved every administrative, scientific and educational segment ofthe Cancer Center, and leading a stepwise but decisive implementation ofthe ensuing strategic directives. Together, the senior leaders prioritized changes in the scientific alignment of Programs and Shared Resources, directed an aggressive and successful faculty recruitment effort that brought to the Cancer Center seven new faculty members appointed at all academic ranks, refocused administrative functions and decision-making processes, identified opportunities for translational and patient-oriented cancer research and developed new initiatives to expand education and mentoring, including for underrepresented minorities. Overall, the senior leadership team has catalyzed the introduction of a productive culture of collaboration and scientific exchange that has transformed the Cancer Center in the last budget period, bringing about expansive gains in NCI and cancer-related funding, and significant increase in collaborative, joint publications across the three Cancer Center Programs. This positive trajectory will continue in the next budget period, when the leadership team will guide the largest faculty and facility expansion of the Cancer Center in forty years enabled by the opening of the new Wistar Research Tower

Public Health Relevance

The newly configured Cancer Center leadership team has successfully leveraged a lean, opportunity-driven administrative infrastructure to bring about expansive gains in cancer focus, collaborative science, joint funding and innovative education to fulfill the vision of the Cancer Center of conquering cancer through outstanding research, education and partnership.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA010815-49
Application #
9438876
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
49
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Saglam, Ozlen; Conejo-Garcia, Jose (2018) PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther 5:
Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426
Duperret, Elizabeth K; Trautz, Aspen; Stoltz, Regina et al. (2018) Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo. Cancer Res 78:6363-6370
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Bhattacharjee, Souvik; Coppens, Isabelle; Mbengue, Alassane et al. (2018) Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance. Blood 131:1234-1247
Fukumoto, Takeshi; Park, Pyoung Hwa; Wu, Shuai et al. (2018) Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22:3393-3400
Thangavel, Chellappagounder; Boopathi, Ettickan; Liu, Yi et al. (2018) Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. Clin Cancer Res 24:1402-1414

Showing the most recent 10 out of 741 publications